• 1.

    Farquhar MG, et al.. The Heymann nephritis antigenic complex: Megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6:3547. https://www.researchgate.net/publication/15620187_The_Heymann_Nephritis_Antigenic_Complex_Megalin_gp330_and_RAP1

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Beck LH Jr, et al.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:1121. doi: 10.1056/NEJMoa0810457

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Tomas NM, et al.. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371:22772287. doi: 10.1056/NEJMoa1409354

  • 4.

    Sethi S. New ‘antigens’ in membranous nephropathy. J Am Soc Nephrol 2021; 32:268278. doi: 10.1681/ASN.2020071082

  • 5.

    A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative study of the adult idiopathic nephrotic syndrome. N Engl J Med 1979; 301:13011306. doi: 10.1056/NEJM197912133012401

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Ponticelli C, et al.. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310:946950. doi: 10.1056/NEJM198404123101503

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Ponticelli C, et al.. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9:444450. https://loyolamedicine.org/sites/default/files/gme/nephrology/pdfs/jasn_1998_treatment_of_mn.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Qin H-Z, et al.. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol 2017; 18:2. doi: 10.1186/s12882-016-0427-z

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Rostoker G, et al.. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63:335341. doi: 10.1159/000187219

  • 10.

    Praga M, et al.. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 2007; 71:924930. doi: 10.1038/sj.ki.5002215

  • 11.

    Ramachandran R, et al.. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep 2017; 2:610616. doi: 10.1016/j.ekir.2017.02.004

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Dahan K, et al.. Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 2017; 28:348358. doi: 10.1681/ASN.2016040449

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Fervenza FC, et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:3646. doi: 10.1056/NEJMoa1814427

  • 14.

    Fernández-Juárez G, et al.. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014; https://www.sciencedirect.com/science/article/pii/S0085253820312515

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Scolari F, et al.. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol [published online ahead of print March 2021]. doi: https://doi.org/10.1681/ASN.2020071091; https://jasn.asnjournals.org/content/early/2021/02/27/ASN.2020071091

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    KDIGO Clinical Practice Guideline on Glomerular Diseases (Kidney Disease, Improving Global Outcomes [KDIGO]). June 2020. Accessed February 25, 2020. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-GN-GL-Public-Review-Draft_1-June-2020.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    van de Logt A-E, et al.. Synthetic ACTH in high risk patients with idiopathic membranous nephropathy: A prospective, open label cohort study. PLoS One 2015; 10:e0142033. doi: 10.1371/journal.pone.0142033

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Barrett C, et al.. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant 2020; 35:599606. doi: 10.1093/ndt/gfz086

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Podestà MA, et al.. Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: Preliminary findings with double filtration plasmapheresis and ofatumumab. Nephron 2020; 144:3035. doi: 10.1159/000501858

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Bontscho J, et al.. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 2011; 22:336348. doi: 10.1681/ASN.2010010034

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Appel G, et al.. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2002; 13:668A. https://www.researchgate.net/publication/312463048_Eculizumab_C5_complement_inhibitor_in_the_treatment_of_idiopathic_membranous_nephropathy

    • PubMed
    • Search Google Scholar
    • Export Citation

Treatment Changes in Membranous Nephropathy

Mayuri Trivedi Mayuri Trivedi, DM, is assistant professor in the Department of Nephrology, Lokmanya Tilak Municipal Medical College and Hospital, Mumbai, India. Zaheer Virani, MD, DNB, is a consultant nephrologist with Prince Aly Khan Hospital, Mumbai, India.

Search for other papers by Mayuri Trivedi in
Current site
Google Scholar
PubMed
Close
and
Zaheer Virani Mayuri Trivedi, DM, is assistant professor in the Department of Nephrology, Lokmanya Tilak Municipal Medical College and Hospital, Mumbai, India. Zaheer Virani, MD, DNB, is a consultant nephrologist with Prince Aly Khan Hospital, Mumbai, India.

Search for other papers by Zaheer Virani in
Current site
Google Scholar
PubMed
Close
Restricted access
Save